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SUMMARY
Glycogen synthase kinase-3 (GSK-3) is a positive regulator of PD-1 expression in
CD8+ T cells and GSK-3 inhibition enhances T cell function and is effective in the
control of tumor growth. GSK-3 has two co-expressed isoforms, GSK-3a and
GSK-3b. Using conditional gene targeting, we demonstrate that both isoforms
contribute to T cell function to different degrees.Gsk3b/mice suppressed tu-
mor growth to the same degree as Gsk3a/b/ mice, whereas Gsk3a/ mice
behaved similarly to wild-type, revealing an important role for GSK-3b in regu-
lating T cell-mediated anti-tumor immunity. The individual GSK-3a and b isoforms
have differential effects on PD-1, IFNg, and granzyme B expression and operate
in synergy to control PD-1 expression and the infiltration of tumors with CD4 and
CD8 T cells. Our data reveal a complex interplay of the GSK-3 isoforms in the con-
trol of tumor immunity and highlight non-redundant activity of GSK-3 isoforms in
T cells, with implications for immunotherapy.
INTRODUCTION
Glycogen synthase kinase-3 (GSK-3) was first discovered in 1980 as a regulatory kinase which phosphory-
lates and inhibits glycogen synthase (Embi et al., 1980) and has since been implicated in several disease
states and key cellular processes, including Wnt, insulin, and Hedgehog signaling (Matthews and Cantrell,
2009). Two isoforms of GSK-3 have been reported in mammals; a 51 kDa GSK-3a and a 47 kDa GSK-3b iso-
form, encoded by the unlinked Gsk3a and Gsk3b genes, respectively. These two isoforms exhibit 98% ho-
mology in their kinase domains but only 36% identity in the last 76 C-terminal amino acid residues. Both
isoforms are highly expressed in many tissues (Woodgett, 1990) and have been implicated in processes
ranging from glycogen metabolism to gene transcription, apoptosis and microtubule stability (Eldar-Fin-
kelman and Martinez, 2011; Frame and Cohen, 2001). GSK-3b is thought to be of prime importance in dia-
betes (McManus et al., 2005), Alzheimer disease (Phiel et al., 2003), and inflammation (Martin et al., 2005).
An unusual aspect of GSK-3 is that it is constitutively active in resting cells (Embi et al., 1980; Woodgett,
1990) and its inactivation occurs through phosphorylation of specific serine residues (Ser9 in GSK-3b,
Ser21 in GSK-3a) (Hughes et al., 1993; Rayasam et al., 2009). This phosphorylation allows the phosphoserine
tail of GSK-3 to bind and block its own active site (Doble and Woodgett, 2003; Rayasam et al., 2009). In
contrast to this, tyrosine phosphorylation of GSK-3 (Tyr216 in GSK-3b, Tyr279 in GSK-3a) enhances its ability
to bind and phosphorylate substrates (Frame and Cohen, 2001; Hughes et al., 1993). Furthermore GSK-3
has a preference for substrates which have already been phosphorylated by a ‘‘priming kinase’’ (Picton
et al., 1982). For example, glycogen synthase is primed by casein kinase 2 (CK2) prior to its subsequent
phosphorylation and inactivation by GSK-3 (Picton et al., 1982).
GSK-3 can phosphorylate more than one hundred substrates (Sutherland, 2011) and plays a key role in T cell
activation (Ohteki et al., 2000; Rudd et al., 2020; Taylor et al., 2016; Taylor and Rudd, 2020). Active GSK-3
blocks T cell activation and cytokine production (Ohteki et al., 2000), and we previously showed that the
inhibition of GSK-3 downregulate PD-1 and LAG-3 gene expression (Taylor et al., 2016). Other substrates
include transcription factors such as cyclic AMP response element binding protein, the nuclear factor of
activated T cells (NFATs), b-catenin, c-Jun, and NF-kB (Cohen and Frame, 2001; Eldar-Finkelman and Mar-
tinez, 2011; Grimes and Jope, 2001). In the case of NFAT, GSK-3 inactivates the pathway by phosphory-
lating NFAT and facilitating its exit from the nucleus in T cells (Beals et al., 1997; Neal and Clipstone,
2001). Active GSK-3 inhibits T cell proliferation (Ohteki et al., 2000), whereas T cell receptor (TCR) and
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CD28 ligation induces GSK-3 phospho-inactivation (Appleman et al., 2002; Ohteki et al., 2000; Wood et al.,
2006) dependent on phosphatidylinositol 3-kinase (PI3-K) (Taylor and Rudd, 2017).
As a regulator of PD-1 and LAG3 expression, we previously showed that small molecule inhibitors (SMIs)
and siRNA down-regulation of GSK-3 are effective in promoting viral clearance (Taylor et al., 2016) and sup-
pressing tumor growth (Taylor et al., 2018). Mechanistically, this was found to operate by enhancing Tbet
(Tbx21) transcription which, in turn, inhibits Pdcd1 gene expression by repressing the Pdcd1 promoter (Hui
et al., 2017; Rudd et al., 2020; Taylor et al., 2016; Taylor & Rudd, 2017, 2019). Tbet also regulates an array of
other genes, including cytokines such as interleukin-2 and effector proteins such as granzyme B which are
needed for optimal CD8 cytolytic function (Lazarevic and Glimcher, 2011; Sullivan et al., 2003). An unan-
swered question concerns the relative roles of the two isoforms of GSK-3 in the modulation of PD-1 and
protective immunity against cancer. Here, we show the alpha and beta isoforms differentially regulate
PD-1, IFNg and Granzyme B expression, whilst deletion of both isoforms synergizes to reduce PD-1 expres-
sion and promote the T cell infiltration into tumors.
RESULTS
Conditional knockout of either or both isoform(s) of GSK-3 does not affect the total number
of splenic T cells
Our previous studies have demonstrated a clear role for GSK-3 in the regulation of tumor growth, with
the inhibition of GSK-3 through SMIs potentiating T cell reactivity leading to diminished growth (Rudd
et al., 2020; Taylor et al., 2018). However, it is unclear if the different isoforms of GSK-3 work in a similar
manner, if both isoforms are required for the function of GSK-3, or if the action of one is dominant over
the other, particularly in the context of cancer. Several SMIs are available for GSK-3 and cited ki values
suggest that it is possible for SMIs to preferentially target one isoform over the other; although in prac-
tice, particularly in vivo, evidence suggests that this is not the case and that inhibitors tend to act against
both isoforms, albeit at varying levels (Lo Monte et al., 2012; Martinez and Perez, 2008). To unequivocally
answer this question, we have used Gsk3a-flox/flox-bflox/flox mice crossed with an Lck-Cre line (Jack-
son labs) which uses the distal Lck promoter to delete both Gsk3a and Gsk3b in post-selection
CD4+CD8+ DP cells without affecting the T cell repertoire (Chiang and Hodes, 2016) to generate Gsk3ab
cKO mice. These mice were then used further to generate individual a and b isoform-specific cKO mice;
Gsk3a-flox/flox-Lck-Cre+ (Gsk3a cKO) and Gsk3b-flox/flox-Lck-Cre+ (Gsk3b cKO), respectively, resulting
in mice with T cells devoid of either GSK-3a or GSK-3b (Figure 1). This was apparent in both CD4 and
CD8 T cell populations as shown in Figure 1A. Importantly, the loss of GSK-3 expression in T cells
had no effect on the total number of CD8+ and CD4+ splenic T cells when compared to control mice
(Figure 1B).
Figure 1. Conditional knockout of GSK-3 alpha or GSK-3 beta either alone or together does not affect the levels
of CD4 or CD8+ T cells
(A) Western blot depicting expression of GSK-3 isoforms; alpha or beta in spleen cells (left panel), purified CD8+ T cells
(middle panel) and purified CD4+ T cells (Right panel) taken from the spleens of GSK-3 conditional knockout mice and wt
littermates.
(B) Percentage of CD8+ (left) or CD4+ (right) CD3 T cells in the spleens of conditional knockout mice, wt littermates and
Lck-cre control mice, as determined by flow cytometry. Data are represented as mean G SEM.
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T cell depletion of Gsk3b, alone or in combination with Gsk3a suppresses growth of two
distinct tumor types
Previously, we showed that usingGSK-3 SMIs in in vivomousemodels of cancer led to suppression of tumor
growth (Taylor et al., 2018). These studies focused on the CD8+ T cell population as the effector cells. How-
ever, SMIs act across all tissues and although CD8+ T cells were investigated ex vivo there is still the pos-
sibility that other cells might play a role within these models. We have now utilized the newly generated
cKOmice to test if GSK-3 deletion in T cells alone is sufficient to suppress tumor growth and whether dele-
tion of both isoforms is required. We first determined the tumor growth rate and survival kinetics in the
three different strains of cKO mice bearing EL4 tumors in the flank (Figure 2A) The mean survival time of
13 days for wt littermate mice was similar to that seen in Gsk3a cKO mice, with the exception of 1 mouse
surviving of 8. In contrast, depletion of Gsk3b alone or in combination with Gsk3a gave a clear increase in
the overall survival rate, with 50% of Gsk3ab cKO mice and 60% of Gsk3b cKO still surviving at day 40. This
survival was concurrent with diminished tumor growth in these animals and the eventual eradication of tu-
mor which was apparent within 15–20 days post-tumor challenge (lower panel Figure 2A). In a repeat study,
EL4 tumor bearing mice were sacrificed at day 10 (when tumors were present in all mice) to analyze splenic
and tumor-infiltrating cells. In agreement with the results from tumor-free animals (Figure 1B), no difference
Figure 2. Depletion of either the GSK-3 beta isoform alone or in combination with GSK-3-alpha in T cells can
protect against EL4 tumor progression
(A) Survival plot (upper panel) of conditional knockout mice as indicated following EL4 tumor cell implantation. Growth
curves of EL4 tumors implanted into GSK-3 cKO mice (lower panel). Numbers in bottom right corner indicate the number
of tumor-free mice after 40 days. n = 8.
(B) Percentage of CD8 (upper panel) and CD4 (lower panel) CD3+ T cells in the spleen as determined by flow cytometry.
(C) Quantitative real-time PCR of splenic T cells taken from animals at day 10.
(D) Percentage of CD8+ (upper left panel), CD4+ (lower left panel), granzyme B (Gzmb) expressing CD8+ (upper right
panel) and IFNg expressing CD8+ tumor-infiltrating cells (TILs) (taken from animals at day 10) as determined by flow
cytometry.
(E) Flow cytometric profiles for T cells isolated from tumor-infiltrating cells (TILs) (data taken from animals at day 10 and
representative of 5 samples).
Data represent three combined independent experiments of n R 5 mice per group. Data are represented as mean G
SEM. Groups compared using unpaired t test. ***p < 0.0001; **p < 0.001; *p < 0.01; ns, no significant difference relative to
controls. Log rank tests performed for Kaplan-Meier survival data.
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was seen in the frequency of splenic CD4+ or CD8+ T cells between the different cKO mice bearing EL4
tumors (Figure 2B). Previous studies using GSK-3 SMIs have shown that control of tumor growth is associ-
ated with a decrease in PD-1 expression, correlated with an increase in the expression of the transcription
factor T-bet (Taylor et al., 2016). Here, using quantitative real-time polymerase chain reaction (qRT-PCR) of
splenic CD8+ T cells, we found Pdcd1 gene expression to be significantly lower in the Gsk3ab cKO
compared to wt littermates, and this was associated with increased Tbx21 expression (Figure 2C). A
decrease in Pdcd1 expression was also seen in the Gsk3b cKO, whilst statistically significant, the reduction
in expression of Pdcd1 in Gsk3b cKO T cells was not as great as that seen in the double cKO. There was no
effect on Pdcd1 expression in Gsk3a cKO cells but all three cKO strains showed increased Tbx21 gene
expression (Figure 2C).
Analysis of the tumors revealed no difference in the infiltration of CD4+ or CD8+ T cells in the double cKO
mice when compared to wt littermates, in agreement with results obtained using GSK-3 SMIs (Taylor et al.,
2018). However, deletion of Gsk3b alone resulted in significantly increased infiltration of both CD4+ and
CD8+ T cells (Figure 2D). Tumor-infiltrating CD8+ T cells from the double cKOmice had significantly higher
levels of granzyme B expression and increased numbers of IFNg expressing cells. Although the latter was
true for all three strains of GSK-3 cKO, the levels of granzyme B were only increased when both GSK-3 iso-
forms were depleted (Figure 2D). These findings indicate that the regulatory effects of GSK-3 on these
events are more nuanced that previously appreciated. It appears the required events that determine tumor
infiltration are different from those needed for the differentiation of T cells leading to Granzyme B expres-
sion. Unlike these differences, cell surface PD-1 expression was measured on tumor-infiltrating lympho-
cytes (TILs) and showed a clear reduction in the double andGsk3b cKOmouse cells (Figure 2E) and a lesser
reduction in TILs from the Gsk3a cKO mice, consistent with the Pdcd1 gene expression data from the
spleen (Figure 2C).
We next sought to confirm the results obtained from cKO mice bearing EL4 tumors with those bearing a
second tumor type, B16 melanoma, and to determine whether deletion of one GSK-3 isoform could
lead to suppression of both flank tumors and pulmonary metastasis. B16 tumor cells tagged with luciferase
were injected intradermally into the three different strains of cKO mice and control animals and the tumor
growth rate and survival kinetics assessed. The wt littermate mice and Gsk3a cKO mice bearing B16 flank
tumors demonstrated a mean survival of 15 and 18 days, respectively, with the exception of 1 surviving
mouse of 8 in the Gsk3a cKO (Figure 3A). In contrast, the double GSK-3 cKO demonstrated a 50% survival
rate at day 50. This was slightly lower in theGsk3b cKO, with 40% of mice surviving at day 50; here increased
survival was associated with diminished tumor growth and the eventual eradication of tumor was apparent
within 15–20 days post-tumor challenge (lower panel Figure 3A). It should be noted that there was an over-
all prolonged survival of theGsk3b cKOmice of 5–10 days compared to all other strains, with tumor growth
being slower in these mice (Figure 3A).
Splenic and tumor-infiltrating cells were analyzed from B16 flank tumor bearing mice which were sacrificed
at day 12 (a time point at which tumors were present in the majority of animals to enable TIL isolation). As
expected, no difference was seen in the number of splenic CD4+ or CD8+ T cells from the different cKO
mice compared to wt littermates (Figure 3B). qRT-PCR of splenic CD8+ T cells demonstrated Pdcd1 tran-
scription to be significantly lower in the double GSK-3 cKO compared to wt littermates, and this was asso-
ciated with increased Tbx21 gene expression (Figure 3C). Furthermore, as seen in the EL4 lymphoma
model, a significant decrease in Pdcd1 gene expression was also seen in the Gsk3b cKO but not in
Gsk3a cKO cells (Figure 3C). All three cKO strains showed increased Tbx21 gene expression.
The Gsk3b cKO had a significantly higher number of infiltrating CD4+ and CD8+ T cells compared to the
other cKOs and wt littermates (Figure 3D). Further analysis demonstrated tumor-infiltrating cells fromGSK-
3 double cKO mice to have higher levels of granzyme B expression compared to the single cKO mice. All
three strains of GSK-3 cKO had increased levels of IFNg expressing TILs compared to wt littermates. Finally,
cell surface PD-1 expression on TILs showed a clear reduction in the double cKO mice cells (Figure 3E),
some reduction in the Gsk3b cKO and little change in the Gsk3a cKO, in agreement with Pdcd1 gene
expression changes observed in spleen (Figure 3C).
The data from both the EL4 (Figure 2) and B16 (Figure 3) flank tumors demonstrate non-redundant activity of
the GSK-3a and GSK-3b isoforms, with genetic inactivation of GSK-3b resulting in enhanced rejection of both
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tumor types in the flank. Human cutaneous melanoma metastasizes to multiple sites, including the lungs and
the B16model can seed tumors in the lung following tail vein injection.We therefore analyzed the requirement
for T cell GSK-3 isoforms in B16 pulmonarymetastasis in our cKOmice. Luciferase tagged B16 tumor cells were
injected intravenously into the different cKO and control mice. At day 24, mice were injected intraperitoneally
with luciferin and scanned by IVIS Lumina imaging; data from five mice from each group are shown along with
the total fluxmeasurements from these groups (Figure 4A). As found in the EL4 and B16 flankmodels, rejection
of B16 pulmonary tumors was enhanced by deletion of GSK-3b, revealed by the Gsk3b cKO and double cKO
mice but not theGsk3a cKOmice (Figure 4A). This was shown further by tracking tumor spread within the lung
at various timepoints (Figure 4B). This method also aided in the tissue collection from mice, ensuring that
spleen and tumor samples were takenwhen tumors were apparent in all the different strains (Day 18). As found
in the flank models, no difference was seen in the number of splenic CD4+ or CD8+ T cells between the
different cKO mice (Figure 4C). Splenic CD8+ T cells from the double cKO and Gsk3b cKO mice showed
the expected reduction in Pdcd1 gene expression and all three strains of cKO mice showed increased
Tbx21 expression (Figure 4D). Analysis of TILs revealed increased infiltration of CD4+ and CD8+ T cells in
theGsk3b cKOmice and all three strains of cKOmice exhibited an increased frequency of CD8+ cells express-
ing granzyme B or IFNg compared to controls (Figure 4E). Collectively, these data demonstrate a key role for
the GSK-3b isoform in controlling T cell mediated anti-tumor immunity.
Figure 3. Depletion of either the GSK-3 beta isoform alone or in combination with GSK-3-alpha in T cells can
protect against B16 flank tumor progression
(A) Survival plot (upper panel) of conditional knockout mice as indicated following B16 tumor cell implantation. Growth
curves of EL4 tumors implanted into GSK-3 cKO mice (lower panel). Numbers in bottom right corner indicate the number
of tumor-free mice after 50 days. n = 8.
(B) Percentage of CD8 (upper panel) and CD4 (lower panel) CD3+ T cells in the spleen as determined by flow cytometry.
(C) Quantitative real-time PCR of splenic T cells taken from animals at day 15.
(D) Percentage of CD8+ (upper left panel), CD4+ (lower left panel), granzyme B (Gzmb) expressing CD8+ (upper right
panel) and IFNg expressing CD8+ tumor-infiltrating cells (TILs) (taken from animals at day 15) as determined by flow
cytometry. E) Flow cytometric profiles for PD-1 expressing T cells isolated from tumor-infiltrating cells (TILs) taken from
animals at day 15 (data representative of 5 samples).
Data represent three combined independent experiments of n R 5 mice per group. Data are represented as mean G
SEM. Groups compared using unpaired t test. ***p < 0.0001; **p < 0.001; *p < 0.01; ns, no significant difference relative to
controls. Log rank tests performed for Kaplan-Meier survival data.
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Tumor rejection in Gsk3b cKO is associated with higher numbers of tumor-infiltrating T cells
Mice injected intravenously with B16 melanoma cells were culled 18 days later and lungs removed for
immunohistochemistry (Figure 5). This timepoint was chosen to ensure that all mice were tumor bearing
as confirmed prior to harvest by in vivo imaging. Staining showed CD4+ and CD8+ T cells to be scattered
throughout the tumor region (Figures 5A and 5B, respectively) however, significantly increased numbers of
CD4+ T cells were apparent in the Gsk3b cKO sections as determined using Imagescope software (Fig-
ure 5A, right panel). Further staining demonstrated all strains to contain PD-1 expressing cells throughout
the tumor (Figure 5). A slight decrease in PD1+ cells was observed in theGsk3b cKO, but this reduction was
only significant when both isoforms were depleted in the double cKO. Interestingly, Foxp3 expression was
significantly increased in all three cKOs compared to wt littermates.
T cell distributions within the peribronchial regions (areas surrounding the tumors rather than within the
tumor itself) were also examined revealing accumulations of CD4+ T cells in the double cKO and Gsk3a
cKO but not the Gsk3b cKO mice (Figure 6A). Furthermore, there was a significant reduction in CD8+
T cells in the Gsk3b cKO mice (Figure 6B). This reduction in peribronchial CD4+ and CD8+ T cells in
the Gsk3b cKO mice was also reflected in lower numbers of Foxp3 and PD1 expressing cells (Figures
6C and 6D). Taken together, these data demonstrate a clear difference in T cell distribution in response
to the presence of tumor growth with a higher level of tumor-infiltrating T cells being seen in the Gsk3b
cKO mice.
Figure 4. Depletion of either the GSK-3 beta isoform alone or in combination with GSK-3-alpha in T cells can
protect against pulmonary metastasis of B16 melanoma
(A) luminescent image (upper panel) showing B16 metastasis at day 24 with total flux (photons/second) values depicted in
the histogram to the right.
(B) Luminescent imaging of conditional knockout mice at time points indicated following B16 tumor cell implantation.
(C) Percentage of CD8 (upper panel) and CD4 (lower panel) CD3+ T cells in the spleen as determined by flow cytometry.
(D) Quantitative real-time PCR of splenic T cells taken from animals at day 18.
(E) Percentage of CD8+ (upper left panel), CD4+ (lower left panel), granzyme B (Gzmb) expressing CD8+ (upper right
panel) and IFNg expressing CD8+ tumor-infiltrating cells (TILs) (taken from animals at day 18) as determined by flow
cytometry. ***p < 0.0001; **p < 0.001; *p < 0.01; ns, no significant difference relative to controls.
Data represent three combined independent experiments of n R 5 mice per group. Data are represented as mean G
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Further to this, lung tissue was taken from a single Gsk3b cKO mouse which had completely rejected the
B16 tumor by day 18 and IHC performed (Figure S1). There was a significant increase in the number of CD4+
T cells and Foxp3 expressing cells in the lungs of this mouse that rejected the tumor. This suggests that
there is an increase in the cells migrating to the tumor site within Gsk3b cKO mice and that they efficiently
infiltrate any tumors and contribute to controlling disease progression.
DISCUSSION
Despite our establishment of the importance of GSK-3 in the activation of T cell function needed for tumor
rejection, the relative roles of the different GSK-3 isoforms in tumor rejection have been unclear. Our results
demonstrate that GSK-3beta activity in T cells provides a more permissive environment for the tumor
models tested here and that deletion of this isoform alone can enhance T cell mediated tumor rejection.
However, the mechanism behind this remains to be fully elucidated. We have previously shown that inhi-
bition of GSK-3 using SMIs leads to down regulation of checkpoint molecules PD-1 and LAG-3, whilst up-
regulating Tbet (Rudd et al., 2020; Taylor et al., 2016). These findings are supported here when genes en-
coding both GSK-3 isoforms are targeted in a cKO model. Furthermore, we show that the two isoforms
contribute in different ways to the various T cell functions linked to tumor rejection. Overall, the GSK-3b
isoform appeared to be dominant over the GSK-3a isoform, although both isoforms were needed for
optimal tumor rejections.
The targeting of theGSK-3b isoform alone also provided a tumor suppressive effect, but themechanismbehind
this may not be the same. There is some reduction in tumor growth, but this is not as striking as that seen when
both isoforms are depleted. This suggests that deletion of the GSK-3a isoform is also needed for optimum sup-
pression of tumor growth, althoughdepletion of theGSK-3a isoformalone failed to showaphenotype.Whether
its contribution was additive in promoting T cell rejection or it operated cooperatively is not clear. It is possible
that the functionof theGSK-3b is in somemanner cross-regulated by theGSK-3a isoformbut howboth isoforms
operate remains unclear. Similar to tumor rejection, depletion ofGsk3a alone, unlikeGsk3b, has no direct effect
Figure 5. Tumor rejection in Gsk-3b cKO is associated with higher numbers of tumor-infiltrating T cells
(A–D) Immunohistochemistry of lung tissue sections from B16 tumor bearing mice. Intra-tumoural areas are shown
following staining for (A) CD4+, (B) CD8+, (C) PD1+ and (D) FOXP3+ expression. End panels depict number of positive
cells quantified from 5 different areas using ImageScope Software.
Data representative of two independent experiments. Groups compared using unpaired t test. ***p < 0.0001; **p < 0.001;
*p < 0.01; ns, no significant difference relative to controls.
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onPD-1expression,whereasdepletionofboth together caused theeffect tobemagnified.Onepossibility is that
theGSK-3b isoform isdirectly involved in thePD-1pathway,whereasGSK-3amayact indirectly, affectinganother
protein which then acts on PD-1 expression. As, GSK-3a alone has no obvious effect on PD-1 expression, this
would suggest that the protein it does act upon is also regulated by GSK-3b and therefore, the effects are
only seen when both isoforms are switched on or off.
Another surprising finding was the suggestion that the two isoforms might differentially affect the CD4 and
CD8 TILs in mice. CD4+ T cells were found to be at higher levels in tumors inGsk3b cKOmice compared to
the levels seen in Gsk3a cKO mice. More surprisingly, these levels were also higher than those seen in the
double cKO mice. Although the increase in the numbers of infiltrating CD8+ T cells did not reach signifi-
cance, it was apparent that some tumor regions had very high levels of CD8+ T cells, whilst others had
very low levels. It may be speculated that had the samples been taken over a time course, an increase in
T cell infiltration would have been more apparent and that perhaps this time point reflects a point at which
CD8+ T cells were moving into the tumor site to attack tumor cells, or indeed they were already migrating
away from these sites after fulfillment of their role. As seen in 40% of these cKOmice, a later time point may
have resulted in no tumor being present and therefore it is possible that this is the recession following the
peak of the immune response. Further analysis into the dynamics of T cell migration and infiltration are war-
ranted to fully understand this aspect of GSK-3 regulation, as are a detailed analysis of the activation and
maturation status of T cells in the different GSK-3 backgrounds; however, this is beyond the scope of the
current manuscript. Regardless of these dynamics, the comparison of the infiltration patterns between
these cKO mice at a specific time point suggests that the beta isoform plays a dominant role in controlling
cellular movement and T cell migration. This finding is consistent with our previous work demonstrating the
inhibition of GSK-3 (by SMIs) reduces motility and increase cell-to-cell contact, this coupled with enhanced
CTL potential, led to tumor suppression (Taylor and Rudd, 2020).
The results showing higher tumor infiltration of T cells due to the beta isoform may be due to chemotactic
effects enhancing migration of these T cells to the tumor site, or T cell retention at the tumor site, resulting
Figure 6. Reduced number of T cells in non-tumoural regions in b16 melanoma bearing Gsk-3b cKO
(A–D) Immunohistochemistry of lung tissue sections from B16 tumor bearing mice. Non-tumor areas are shown following
staining for (A) CD4+, (B) CD8+, (C) PD1+ and (D) FOXP3+ expression. End panels depict number of positive cells
quantified from 5 different areas using ImageScope Software.
Data are representative of two independent experiments. Groups compared using unpaired t test. ***p < 0.0001; **p <
0.001; *p < 0.01; ns, no significant difference relative to controls.
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in prolonged contact and efficient killing of the tumor cells. Oddly, this effect is not seen in the Gsk3a cKO
mice, nor in the double cKO which suggests a possible opposing effect of the alpha isoform. The data out-
lines a possible complex interplay between the two isoforms, each playing their own part in different path-
ways, but yet together synergizing to reduce PD-1 expression, an effect which was optimally seen when
both isoforms are depleted.
Previously our work has focused on CD8 T cells, more specifically cytotoxic T cells and their enhanced ability
to kill tumor cells when GSK-3 is inactivated. However, these results clearly demonstrate that the GSK-3b
isoform also impacts upon CD4+ T cells in the context of tumor immunity. Previous work has shown that
GSK-3b is important for the differentiation of Th17 cells (Beurel et al., 2011), whilst GSK-3a is needed for
Th1 cells (Beurel et al., 2013). Further investigation into the role of both isoforms in the different subsets
is warranted to fully understand the mechanisms behind GSK-3 regulation in controlling the immune
response. Such studies could potentially lead to new targeted therapeutic approaches.
Limitations of the study
This study focused on determining the relative contributions of the two isoforms of GSK-3 on T cell-medi-
ated tumor immunity. Our investigation extended to CD8+ T cells and the expression of PD-1 and Tbet by
these cells as indicated from our previous work using GSK-3 inhibitors. Our results reveal both overlapping
and non-redundant functions of the isoforms, but the detailedmechanisms by which the two isoforms regu-
late the T cell phenotype remain unclear at this time. A detailed understanding of themechanisms by which
GSK-3 regulates T cell activity requires analysis of T cell activation and maturation status in the different
GSK-3 backgrounds. In addition, determination of the pathways downstream of the two isoforms and
further mechanistic studies of T cell migration and tumor infiltration will reveal the pathways by which
GSK-3 regulates T cell activity. These mechanistic studies were beyond the scope of the current study.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by
the Lead Contact, Dr. Alison.Taylor (a.taylor1@leeds.ac.uk).
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-CD8a (clone, 53-6.7) ebioscience CAT#12-0081-81; RRID:AB_465529
anti-CD4 (clone, RM4–5) ebioscience CAT#MCD0420; RRID:AB_10373704
IFN gamma Monoclonal Antibody (XMG1.2) ebioscience CAT#45-7311-82; RRID:AB_1107020
CD3e Monoclonal Antibody (145-2C11) ebioscience CAT#17-0031-82; RRID:AB_469315
Granzyme B Monoclonal Antibody (NGZB),
PE-Cyanine7
ebioscience CAT# 25-8898-82; RRID:AB_10853339
Recombinant Anti-CD4 antibody [EPR19514] Abcam plc CAT#ab183685; RRID:AB_2686917
Recombinant Anti-CD8 alpha antibody [EPR21769] Abcam plc CAT#ab217344; RRID:AB_2890649
PD-1 (D7D5W) XP Rabbit mAb (Mouse Specific) Cell Signaling Technology CAT#84651S; RRID:AB_2800041
FoxP3 (D6O8R) Rabbit mAb Cell Signaling Technology CAT#12653S; RRID:AB_2797979
Critical Commercial Assays
RNeasy Mini kit Qiagen Cat# 74104
TaqMan Reverse Transcription Reagents Applied Biosystems Cat# N808-0234
SYBR Green PCR Master Mix Applied Biosystems Cat# 4309155
ImmPACT DAB Substrate, Peroxidase (HRP) Vector CAT#SK-4105
ImmPRESS HRP Horse Anti-Mouse IgG PLUS
Polymer Kit, Peroxidase
Vector CAT#MP-7802
Experimental Models: Cell Lines
B16-F10-Luc2 (ATCC CRL-6475-LUC2) ATCC Cat# CRL-6475-LUC2
EL4 (ATCC TIB-39) ATCC CAT#TIB-39
Experimental Models: Organisms/Strains
Mouse: 012837 - B6.Cg-Tg(Lck-icre)3779Nik/J Jackson Laboratories CAT#012837
Mouse:Gsk3a-flox/flox-b-flox/flox James Woodgett
Oligonucleotides
PD-1-FW, 5-CCGCCTTCTGTAATGGTTTGA-3; Thermo Fisher Scientific https://www.thermofisher.com/
PD-1-RV, 5-GGGCAGCTGTATGATCTGGAA-3; Thermo Fisher Scientific https://www.thermofisher.com/
GAPDH-FW, 5-CAACAGCAACTCCCACTCTTC-3; Thermo Fisher Scientific https://www.thermofisher.com/
GAPDH- RW, 5- GGTCCAGGGTT TCTTACTCCTT-3 Thermo Fisher Scientific https://www.thermofisher.com/
Tbet-FW, 5-GATCGTCCTGCAGTCTCTCC-3; Thermo Fisher Scientific https://www.thermofisher.com/
Tbet-RW, 5-AACTGTGTTCCCGAGGT GTC-3; Thermo Fisher Scientific https://www.thermofisher.com/
Software and Algorithms
Prism GraphPad https://www.graphpad.comRRID:SCR_002798
CytExpert Beckman Coulter https://www.mybeckman.uk/flowcytometry/
instruments/cytoflex/software
Aperio and Imagescope software Leica Biosystems www.Leicabiosystems.com
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This study did not generate any new unique reagents.
Data and code availability
This study did not generate/analyse any datasets/code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Gsk3a-flox/flox-bflox/floxmice were crossed with an Lck-Cre line (Jackson labs) both on a C57BL/6J back-
ground. Mice heterozygous for the floxed genes were backcrossed to give mice which were homozygous
for the floxed gene and hemizygous for lck-cre. Mice have been backcrossed for more than 10 generations
to establish three separate breeding colonies of Gsk3a-flox/flox-bflox/flox-Lck-Cre+ (Gsk3ab cKO),
Gsk3a-flox/flox-Lck-Cre+ (Gsk3a cKO) and Gsk3b-flox/flox-Lck-Cre+ (Gsk3b cKO) mice. Breeding mice
hemizygous for Lck-cre resulted in litters consisting of approx. 50% floxed-Lck-cre+ animals and 50%
floxed-Lck-cre- mice. The latter were used as wild type littermates (containing floxed genes without Lck-
cre) which were used as controls alongside Lck-cre only mice. Both female and male animals aged between
6 and 10 weeks were randomly subjected to the experiments and there was no difference in experimental
results due to sex differences. The research was regulated under the Animals (Scientific Procedures) Act
1986 Amendment Regulations 2012 Home Office UK PPL Nos. 70/7544 and P0CFA732A.
Primary T cell cultures
Spleen cells were treated with a hypotonic buffer with 0.15M NH4CL, 10mM KHCO3 and 0.1mM EDTA, pH
7.2 to eliminate red blood cells before suspension in RPMI 1640 medium supplemented with 10% FCS,
50uM beta-mercaptoethanol, sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin and streptomycin
(GIBCO). T cells were isolated from tumor-infiltrating cells, spleen and lymph node samples using negative
section of magnetically labeled cells (Miltenyi). In some cases, whole lymphocyte samples were used for
flow cytometry to determine effect on other cell sub-types.
Cell lines
Tumor cells included B16 F10melanoma and EL4 lymphoma cells (obtained from the ATCC). Cell lines were
cultured in DMEM medium supplemented with 10% FCS, 50uM beta-mercaptoethanol, sodium pyruvate,
2 mM L-glutamine, 100 U/ml penicillin and streptomycin (GIBCO). Each cell line was grown to achieve
adequate numbers for freezing, followed by repeated thawing for use in the described experiments.
The length and time between thawing and use in experiments was on average 2-3 weeks. The cell lines
were authenticated by means cell surface staining and flow cytometry for characteristic markers and by
their growth properties as described in the literature. Cell cultures were occasionally tested for myco-
plasma (last tested in 2011).
METHOD DETAILS
Flow cytometry
Flow cytometry of antibody staining of surface receptors was conducted by suspending 106 cells in 100ml
PBS and adding antibody (1:100) for 2hr at 4C. Cells were then washed twice in PBS and in some cases
suspended in 100ml PBS with secondary antibody for a further 1h at 4C. Cell staining was analyzed on a
Beckman Coulter CytoFLEX S flow cytometer and by CytExpert software. For intracellular staining, cells
were fixed in 4% paraformaldehyde (PFA), permeabilized with 0.3% saponin (Sigma–Aldrich) and stained
with the desired antibody in saponin containing PBS for 2hr at 4C, followed by a secondary Ab incubation
where primary antibodies were not conjugated.
Antibodies and reagents
The following antibodies were used in experiments; conjugated antibodies for flow cytometry: anti-CD8a
(clone, 53-6.7), anti-CD4 (clone, RM4–5), anti-IFNg, anti-CD3, anti-Granzyme B (ebioscience). Antibodies
for IHC: anti-PD1 and anti-FOXP3 (Cell Signaling Technology), anti-CD8 and anti-CD4 (Abcam)
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Quantitative real-time polymerase chain reaction (PCR)
Single-strand cDNA was synthesized with an RT-PCR kit (Qiagen) according to the manufacturer’s instruc-
tions. Reverse transcription was performed using the RNA polymerase chain reaction (PCR) core kit
(Applied Biosystems). Quantitative real-time PCR used SYBR green technology (Applied biosystems) on
cDNA generated from the reverse transcription of purified RNA. After preamplification (95C for 2 min),
the PCRs were amplified for 40 cycles (95C for 15s and 60C for 60s) in a sequence detection system
(PE Prism 7000; Perkin-Elmer Applied Biosystems). The exponential phase, linear phase and plateau phase
of PCR amplification were carefully monitored to ensure a measurement of real time transcription (33).






GAPDH- RW, 5- GGTCCAGGGTT TCTTACTCCTT-3
Immunohistochemistry
IHC was performed on formalin-fixed paraffin-embedded tissue sections. Following dewaxing, rehydra-
tion, and endogenous peroxidase blocking by a 3% solution of H2O2 (Sigma) for 20 min. Antigen retrieval
was performed using citrate or Tris-EDTA buffers as per antibody datasheets. Nonspecific antibody bind-
ing was blocked by incubation with either horse or goat serum (Vector). Primary antibodies were diluted
1:500 (PD1, FOXP3) or 1:200 (CD4, CD8) in Antibody dilution buffer (Life Technologies #003218) and
were applied for 1h at room temp. Following two washes in TBS, ready-to-use secondary antibodies
were applied (ImmPRESSTM HRP reagent kits, Vector). Sections were washed twice in TBS and Im-
mPACTTM DAB (Vector) was used to detect immunolabeling. Sections were counterstained in hematoxy-
lin, and following dehydration and clearing in xylene, were mounted in distyrene/plasticizer/xylene. Sec-
tions were scanned using Aperio and Imagescope software (Leica Biosystems) was used to determine
percentage positive cells.
Melanoma lung tumor establishment
B16 melanoma cells (2 x 105 taken from the log phase of in vitro growth) OVA-peptide pulsed or non-
pulsed) were transferred intravenously into GSK-3 cKO, wt littermates or lck-cre mice 8-10 weeks old.
Live imaging was performed at the timepoints indicated. Mice were injected intraperitoneally with luciferin
(2 ug per mouse), anaesthetized with isoflurane and scanned with an IVIS Lumina (Caliper Life Sciences). For
quantitative comparisons, we used Living Image software (Caliper Life Sciences) to obtain the maximum
radiance (photons per s per cm2 per steradian, i.e. photons s1 cm2 sr1) over each region of interest,
relative to a negative control region.
Intradermal tumor establishment
EL4 or B16 tumor cells were taken from the log phase of in vitro growth (approx. 70% confluency). They were
then washed and injected into mice (typically 3 x 106 cells for EL4 and 2 x 105 for B16 cells). Tumors were
clearly visible after 1 week and grew progressively in an encapsulated fashion. Induced tumors were
measured on a daily basis using a vernier caliper. Tumors, spleens and lymph nodes were harvested as indi-
cated, or when the tumor reached a maximum diameter of 15mm.
Isolation of tumor-infiltrating lymphocytes (TILs)
Solid tumors or nodules from lungs were harvested from mice at the time indicated. Tissue was disrupted
using a blade and then incubated in HBSS solution containing 200units/ml of collagenase at 37oC for 2 hrs.
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Tissue was then passed through a strainer and cells collected and layered onto ficoll before centrifugation.
Tumor-infiltrating cells were then collected from the lymphocyte layer.
QUANTIFICATION AND STATISTICAL ANALYSIS
The mean and SE of each treatment group were calculated for all experiments. The number of samples is
indicated in the figure legends. Unpaired Student’s t tests or ANOVA tests were performed using the InStat
3.0 software (GraphPad). In certain instances, statistics were done using 2-way ANOVA, or by non-para-
metric Mann Whitney at each time point. * P < 0.05, ** P < 0.01, *** P < 0.001. Log rank tests for Kaplan-
Meier survival data were performed to determine significant differences.
ll
OPEN ACCESS
iScience 24, 102555, June 25, 2021 15
iScience
Article
